Paula T Trzepacz

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:45-52. 2011
  2. doi Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia
    Paula T Trzepacz
    Eli Lilly and Company, Indianapolis, IN, USA Indiana University School of Medicine, Indianapolis, IN, USA Electronic address
    Neurobiol Aging 35:143-51. 2014
  3. doi PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Postgrad Med 123:89-95. 2011
  4. pmc Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts
    Paula T Trzepacz
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Geriatr Psychiatry 21:607-22. 2013
  5. pmc Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease
    Paula T Trzepacz
    Lilly Research Laboratories, Indianapolis, IN, USA Indiana University School of Medicine, Indianapolis, IN, USA Electronic address
    Alzheimers Dement 9:S95-S104.e1. 2013
  6. doi Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
  7. doi Rasch analysis of the orientation log and reconsideration of the latent construct during inpatient rehabilitation
    Jacob Kean
    Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Head Trauma Rehabil 26:364-74. 2011
  8. pmc A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
    Himanshu P Upadhyaya
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 226:189-200. 2013
  9. ncbi Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 20:1371-6. 2004
  10. ncbi Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania
    Robert W Baker
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Br J Psychiatry 185:472-8. 2004

Detail Information

Publications17

  1. doi Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:45-52. 2011
    ....
  2. doi Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia
    Paula T Trzepacz
    Eli Lilly and Company, Indianapolis, IN, USA Indiana University School of Medicine, Indianapolis, IN, USA Electronic address
    Neurobiol Aging 35:143-51. 2014
    ..Individually, PIB-PET generated the best sensitivity, and fluorodeoxyglucose PET had the lowest. Among individual brain regions, the temporal cortex was found to be most predictive for MRI and PIB-PET...
  3. doi PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Postgrad Med 123:89-95. 2011
    ..The PDI-4A may additionally help primary care physicians identify patients with PA, SP, OCD, hypochondriasis, and PTSD...
  4. pmc Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts
    Paula T Trzepacz
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am J Geriatr Psychiatry 21:607-22. 2013
    ..Based on existing exploratory literature, we report preliminary validation of three NPI Questionnaire (NPI-Q-10) subscales that measure clinically meaningful symptom clusters...
  5. pmc Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease
    Paula T Trzepacz
    Lilly Research Laboratories, Indianapolis, IN, USA Indiana University School of Medicine, Indianapolis, IN, USA Electronic address
    Alzheimers Dement 9:S95-S104.e1. 2013
    ..The neuroanatomy of agitation and aggression in Alzheimer's disease is not well understood...
  6. doi Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
    ..The present work examined suicide-related events in acute, double-blind, and placebo- or active comparator-controlled trials with atomoxetine...
  7. doi Rasch analysis of the orientation log and reconsideration of the latent construct during inpatient rehabilitation
    Jacob Kean
    Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Head Trauma Rehabil 26:364-74. 2011
    ....
  8. pmc A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
    Himanshu P Upadhyaya
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 226:189-200. 2013
    ..It was classified as an unscheduled medication indicating a low potential for abuse. However, the abuse potential of atomoxetine has not been reviewed...
  9. ncbi Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania
    Lizheng Shi
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 20:1371-6. 2004
    ....
  10. ncbi Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania
    Robert W Baker
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Br J Psychiatry 185:472-8. 2004
    ..Few controlled studies examine the treatment of depressive features in mania...
  11. doi Phenotype of subsyndromal delirium using pooled multicultural Delirium Rating Scale--Revised-98 data
    Paula T Trzepacz
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    J Psychosom Res 73:10-7. 2012
    ..There is no consensus definition for the phenotype of subsyndromal delirium (SSD), a subthreshold state to full delirium. Without an a priori definition we applied advanced analytic techniques to discern SSD...
  12. ncbi Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study
    Lenard Adler
    From the New York University School of Medicine and New York VA Harbor Healthcare System, New York, NY Eli Lilly and Company, Neuroscience, Indianapolis, IN inVentiv Health Clinical, LLC, Ann Arbor, MI University of Mississippi Medical School, Jackson, MS Tufts University School of Medicine, Boston, MA Indiana University School of Medicine, Indianapolis, IN and Lilly Research Laboratories, Kobe, Japan
    J Clin Psychopharmacol 34:461-6. 2014
    ....
  13. pmc Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Int Psychogeriatr 25:707-19. 2013
    ..Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer's disease (AD)...
  14. doi Initial validation of a brief provisional diagnostic scale for delirium
    Jacob Kean
    Department of Speech and Hearing Sciences, Indiana University, Bloomington, IN, USA
    Brain Inj 24:1222-30. 2010
    ..This study evaluated its accuracy and validity in a population of participants with acquired brain injury (ABI)...
  15. ncbi CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Eur Neuropsychopharmacol 18:79-86. 2008
    ..Results suggest genotyping is unnecessary during routine clinical management, because investigators were able to dose atomoxetine to comparable efficacy and safety levels in EMs and PMs without knowledge of genotype metabolizer status...
  16. doi A provisional screening instrument for four common mental disorders in adult primary care patients
    John P Houston
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Psychosomatics 52:48-55. 2011
    ..To develop an adult self-report instrument for provisional diagnosis of four common mental disorders in primary care patients...
  17. ncbi Designing clinical trials for the treatment of delirium
    Paula T Trzepacz
    Lilly Research Laboratories, Neurosciences Platform Team, Indianapolis, IN 46285, USA
    J Psychosom Res 65:299-307. 2008
    ....